Status:
COMPLETED
Retinal Imaging With Oblique Illumination
Lead Sponsor:
Moser Christophe
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Eye Hospital Jules Gonin
Conditions:
Retinal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Retinal diseases are the major cause of blindness in industrialized countries and while tremendous effort is made to develop novel therapeutic strategies to rescue retinal cells, optimal means to eval...
Eligibility Criteria
Inclusion
- Group 1
- Individuals, 18 to 50 yo, with normal eye fundus.
- Emmetropic or ametropic between +3D and -3D
- Group 2
- Individuals, 18 to 50 yo, with normal eye fundus.
- Myopic between -6D and -12D.
- Group 3
- Individuals over the age of 50 and age-matched to patients with AMD.
- With nwith normal eye fundus.
- Astigmatic, myopic (\<-12D) or presbyopic participants may be included
- Group 4
- Patient over 50 yo, with early or intermediate AMD, including extrafoveolar geographic atrophy
- with visual acuity ≥ 0.6 and clinical judgment of good central fixation.
- Group 5
- Patient over 18, with other retinopathy than AMD,
- with visual acuity ≥ 0.6 and nd clinical judgment of good fixation
Exclusion
- Eye with
- RPE detachment
- a clinically unclear situation
- abnormality preventing good visualization of the fundus
- less than 3 months post-surgery of the anterior segment
- less than 6 months post-surgery of the posterior segment
- active uveitis - myopia ≥12D, hyperopia \> +5D, astigmatism \> 4D
- contraindication to dilatation
- a palpebral opening that is less than 6 mm in height
- Individual:
- albino - unable to fix a target at least 10 seconds
- who does not tolerate being in the dark for 30 minutes
- unable to follow the procedures of the study
- refusing to be informed of the incidental discovery of a clinically significant pathology Investigators of the study, their family members, collaborators and students
Key Trial Info
Start Date :
August 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2022
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04398394
Start Date
August 11 2020
End Date
April 28 2022
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jules Gonin eye hospital
Lausanne, Switzerland, 1015